Search Results - "KOTAKA, M"

Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial by Yamazaki, K., Yamanaka, T., Shiozawa, M., Manaka, D., Kotaka, M., Gamoh, M., Shiomi, A., Makiyama, A., Munemoto, Y., Rikiyama, T., Fukunaga, M., Ueki, T., Shitara, K., Shinkai, H., Tanida, N., Oki, E., Sunami, E., Ohtsu, A., Maehara, Y., Yoshino, T.

“…Oxaliplatin-based adjuvant chemotherapy may be associated with debilitating peripheral sensory neuropathy (PSN) in patients with high-risk stage II colon…”
Get full text

SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer by Munemoto, Y., Nakamura, M., Takahashi, M., Kotaka, M., Kuroda, H., Kato, T., Minagawa, N., Noura, S., Fukunaga, M., Kuramochi, H., Touyama, T., Takahashi, T., Miwa, K., Satake, H., Kurosawa, S., Miura, T., Mishima, H., Sakamoto, J., Oba, K., Nagata, N.

“…Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal…”
Get full text

Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy by Kanai, M., Kawaguchi, T., Kotaka, M., Manaka, D., Hasegawa, J., Takagane, A., Munemoto, Y., Kato, T., Eto, T., Touyama, T., Matsui, T., Shinozaki, K., Matsumoto, S., Mizushima, T., Mori, M., Sakamoto, J., Ohtsu, A., Yoshino, T., Saji, S., Matsuda, F.

“…The severity of oxaliplatin (L-OHP)-induced peripheral sensory neuropathy (PSN) exhibits substantial interpatient variability, and some patients suffer from…”
Get full text

Dose finding phase Ib study of triplet plus cetuximab for patients with wild-type RAS gene metastatic colorectal cancer (TRICETSU study) by Satake, H., Kotake, T., Okita, Y., Hatachi, Y., Yasui, H., Kotaka, M., Kato, T., Tsuji, A.

Get full text

Trifluridine/tipiracil vs regorafenib as salvage-line treatment in patients with metastatic colorectal cancer: A multicenter retrospective study by Kotaka, M., Ogata, M., Ogata, T., Hatachi, Y., Yasui, H., Kato, T., Tsuji, A., Satake, H.

Get full text

Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial) by Kanai, M., Kawaguchi, T., Kotaka, M., Shinozaki, K., Touyama, T., Manaka, D., Ishigure, K., Hasegawa, J., Munemoto, Y., Matsui, T., Takagane, A., Ishikawa, H., Matsumoto, S., Sakamoto, J., Saji, S., Yoshino, T., Ohtsu, A., Watanabe, T., Matsuda, F.

“…Peripheral sensory neuropathy (PSN) is a dose-limiting toxicity of oxaliplatin-based chemotherapy. Several genetic markers have been shown to predict…”
Get full text

Efficacy and safety of a recombinant soluble human thrombomodulin (ART-123) in preventing oxaliplatin induced peripheral neuropathy (OIPN): Results of a placebo-controlled, randomized, double-blind phase II study by Kato, T., Kotaka, M., Satake, H., Makiyama, A., Tsuji, Y., Shinozaki, K., Fujiwara, T., Mizushima, T., Harihara, Y., Nagata, N., Kurihara, N., Kagawa, Y., Kusakawa, G., Sakai, T., Uchida, Y., Takamoto, M., Asami, S., Ando, M., Saito, Y., Hyodo, I.

Get full text

Phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results by Kagawa, Y., Satake, H., Kato, T., Oba, K., Yasui, H., Nakamura, M., Watanabe, T., Hirata, K., Muro, K., Komatsu, Y., Yoshino, T., Yamazaki, K., Mishima, H., Kotaka, M., Tsuji, A., Kakeji, Y., Oki, E., Nagata, N., Junichi, S.

Get full text

A feasibility study of edoxaban for the cancer-associated asymptomatic venous thromboembolism in Japanese gastrointestinal cancer patients receiving chemotherapy (ExCAVE study) by Nakamura, M., Yagisawa, M., Saiki, T., Ishiguro, A., Sawada, K., Yuki, S., Sasaki, T., Ando, T., Ohori, H., Kotaka, M., Muto, O., Shindo, Y., Nakashima, K., Hosokawa, A., Doi, A., Izawa, N., Sunakawa, Y., Satoh, A., Ono, K., Komatsu, Y.

Get full text

Initial report of a phase I/II study of S-1 and irinotecan (IRIS) in combination with cetuximab in patients with wild-type RAS metastatic colorectal cancer by Oki, E, Samura, H, Okumura, H, Ohchi, T, Orita, H, Kobayashi, K, Kinjo, T, Mori, S, Touyama, T, Ohgaki, K, Kawanaka, H, Makiyama, A, Ureshino, N, Kotaka, M, Shimose, T, Saeki, H, Nishimaki, T, Baba, H, Maehara, Y

Get full text

SAPPHIRE: A randomized phase II study of oxaliplatin discontinuation after 6 cycles of mFOLFOX6 + panitumumab therapy in patients with colorectal cancer: Final analysis of efficacy and safety results by Takahashi, M., Munemoto, Y., Nakamura, M., Kotaka, M., Kuroda, H., Kato, T., Minagawa, N., Noura, S., Fukunaga, M., Kuramochi, H., Touyama, T., Takahashi, T., Akagi, Y., Satake, H., Kurosawa, S., Miura, T., Mishima, H., Sakamoto, J., Oba, K., Nagata, N.

Get full text

Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress by Kato, T., Satake, H., Oba, K., Kagawa, Y., Yasui, H., Nakamura, M., Watanabe, T., Matsumoto, T., Hirata, K., Muro, K., Komatsu, Y., Yoshino, T., Yamazaki, K., Mishima, H., Kotaka, M., Tsuji, A., Kakeji, Y., Oki, E., Nagata, N., Sakamoto, J.

Get full text

Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration by Takeuchi, S., Yoshino, T., Yamanaka, T., Kotaka, M., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Bando, H., Taniguchi, H., Gamoh, M., Shiozawa, M., Saji, S., Maehara, Y., Mizushima, T., Ohtsu, A., Mori, M.

Get full text

A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) refractory to standard chemotherapy: APOLLON study by Yamazaki, K., Yasui, H., Yamaguchi, K., Kagawa, Y., Kuboki, Y., Yoshino, T., Gamoh, M., Komatsu, Y., Satake, H., Goto, M., Tanioka, H., Oki, E., Kotaka, M., Makiyama, A., Denda, T., Soeda, J., Shibya, K., Iwata, M., Oba, K., Kato, T.

Get full text

Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies by Oki, E., Nakanishi, R., Ando, K., Takemasa, I., Watanabe, J., Matsuhashi, N., Kato, T., Kagawa, Y., Kotaka, M., Hirata, K., Sugiyama, M., Kusumoto, T., Miyamoto, Y., Toyosaki, K., Kishimoto, J., Kimura, Y., Yoshizumi, T., Nakamura, Y.

“…International treatment guidelines recommend tumor resection for patients with oligometastatic colorectal cancer (CRC). Despite this, recurrence occurs in ∼60%…”
Get full text

P-159Regorafenib vs TAS-102 as salvage-line treatment in patients with metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study by Kotaka, M, Satake, H, Okita, Y, Hatachi, Y, Kotake, T, Hashida, H, Kato, T, Tsuji, A

Get full text

Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer (mCRC): A preplanned analysis of the phase III AXEPT trial by Xu, R., Muro, K., Kim, T.W., Park, Y.S., Wang, W., Han, S.-W., Kotaka, M., Deng, Y.-H., Ahn, J.B., Nakamura, M., Ba, Y., Cho, S.-H., Kato, T., Zhang, T., Lee, K.-W., Matsuoka, H., Fang, W.-J., Morita, S., Iwasa, S., Junichi, S.

Get full text

Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer by Masuishi, T, Suzuki, T, Sukawa, Y, Imamura, C K, Satake, H, Kumekawa, Y, Funakoshi, S, Kotaka, M, Horie, Y, Kawai, S, Okuda, H, Terazawa, T, Kondoh, C, Kato, K, Yoshimura, K, Ishikawa, H, Hamamoto, Y, Boku, N, Kanai, T, Takaishi, H

Get full text

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16 by Yasui, H., Okita, Y., Nakamura, M., Sagawa, T., Watanabe, T., Kataoka, K., Manaka, D., Shiraishi, K., Akazawa, N., Okuno, T., Shimura, T., Shiozawa, M., Sunakawa, Y., Ota, H., Kotaka, M., Okuyama, H., Takeuchi, M., Ichikawa, W., Fujii, M., Tsuji, A.

“…Chemotherapy in combination with anti-epidermal growth factor receptor (EGFR) antibody is considered a first-line treatment regimen for RAS wild-type and…”
Get full text

Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration by Yoshino, T., Yamanaka, T., Kotaka, M., Manaka, D., Eto, T., Hasegawa, J., Takagane, A., Nakamura, M., Kato, T., Munemoto, Y., Nakamura, F., Bando, H., Taniguchi, H., Gamoh, M., Shiozawa, M., Sakamoto, J., Saji, S., Mizushima, T., Ohtsu, A., Mori, M.

Get full text